Dermatologic adverse events associated with epidermal growth factor receptor inhibitors: current concepts of interdisciplinary problem
Epidermal growth factor receptor inhibitors (EGFR) have a high rate of class-specific dermatologic adverse events. Supportive treatment of dermatologic adverse events decreases their severity, minimizes the need for dose de-escalation / discontinuation of targeted therapy, improves commitment to ant...
Saved in:
| Main Authors: | A. S. Polonskaia, E. A. Shatokhina, L. S. Kruglova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-02-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/722 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Acneiform rash — skin toxic reaction to the use of EGFR inhibitors
by: E. A. Shatokhina, et al.
Published: (2019-01-01) -
Pharmacist intervention and identification of adverse events related to treatment efficacy in cancer chemotherapy to improve clinical outcomes
by: Hironori Fujii
Published: (2024-12-01) -
Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity
by: Aashita, et al.
Published: (2025-04-01) -
Best evidence summary for preventing and preventing epidermal growth factor receptor inhibitors induced paronychia in cancer patients
by: Kexuan Li, et al.
Published: (2025-04-01) -
Association between efficacy and skin rash following treatment with the lapatinib in metastatic breast cancer
by: Suleyman Temiz, et al.
Published: (2016-04-01)